He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Subscribe To Our Newsletter & Stay Updated
